A cosmeceutical is defined as a product that is marketed as a cosmetic but has the capacity to exert pharmaceutical effects. In recent years, exosomes have been utilized within the global cosmetics industry to manufacture and market skincare products that use the power of these small extracellular vesicles to enhance a broad range of traits, including but not limited to skin health and rejuvenation, scar improvement, hair regrowth, anti-aging effects, and beyond. Exosomes can provide bioactive substances such as proteins, lipids, and nucleic acids to the target cells to alter gene expression and cellular function. Importantly, exosomes can also induce collagen formation, enhance tissue regeneration, and exert anti-inflammatory properties. [Read more…]
The Rise of Stem Cell Exosomes and their Applications
Exosomes are small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. In the early 1960s, Ernest A. McCulloch and James E. started several experiments leading to the discovery of stem cells. It was not until much later in 1987 that exosomes were first identified in a mammalian reticulocyte (red blood cell)[1] and not until 2007 that exosome-mediated transfer of mRNAs and microRNAs was identified as a “novel mechanism of genetic exchange between cells.”[2] [Read more…]
Global Exosome-Based Aesthetics (Cosmeceuticals) Market
Cosmeceuticals—cosmetic products that deliver pharmaceutical-like benefits—are a rapidly growing sector of the cosmetic and anti-aging industry. Among the most exciting innovations are exosomes, small extracellular vesicles that transport bioactive substances such as proteins, lipids, and nucleic acids to target cells, influencing gene expression and cellular behavior. Their ability to promote collagen production, tissue regeneration, and anti-inflammatory effects has positioned them as powerful tools in skincare and cosmetic applications. [Read more…]
RoosterBio and MineBio Life Sciences Partner to Expand Access to Scalable, High Quality MSC and Exosome Bioprocessing Solutions in China
Partnership Delivers RoosterBio’s Research-Grade and CliniControlTM cGMP Media Platforms to China’s Leading Cell and Gene Therapy Developers; MineBio Holds Import Approval for Immediate Order Fulfillment
FREDERICK, MD., April 8, 2026 — RoosterBio, Inc., a leading supplier of human mesenchymal stem/stromal cells (hMSCs), highly engineered bioprocess media, and advanced therapy manufacturing solutions for hMSCs and exosomes, today announced an exclusive distributor partnership with MineBio Life Sciences Limited (MineBio), a trusted partner to China’s biopharmaceutical and advanced therapy community. Under the agreement, MineBio will distribute RoosterBio’s full platform of research-grade and CliniControlTM cGMP-grade MSC and exosome bioprocessing media throughout China. Critically, MineBio has already secured import approval for RoosterBio’s research use only and cGMP CliniControlTM MSC and exosome bioprocessing media platform, enabling orders to be fulfilled without delay. [Read more…]
World-First EXO 001 Exosome Platform Enables In Vivo Multi-Target CAR-T for Solid Tumors
Jointly developed by China Medical University Hospital and Ever Supreme Bio Technology, the platform demonstrates compelling preclinical tumor clearance across multiple models
TAICHUNG, Feb. 13, 2026 — Cancer has long ranked among the leading causes of death in Taiwan, and solid tumors account for more than 90% of cancer cases worldwide—making them the most challenging frontier for CAR-T cell therapy. China Medical University Hospital (CMUH) announced today that, in collaboration with Ever Supreme Bio Technology, it has successfully developed the world’s first EXO 001 targeted exosome platform, a breakthrough technology that enables direct in vivo programming of T cells to generate multi-target nanobody-based CAR-T cells. [Read more…]
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 27
- Next Page »




